| Scott David Mcclellan, MD | |
|
2115 Neuse Blvd, New Bern, NC 28560-4309 | |
| (252) 633-4461 | |
| (252) 633-6016 |
| Full Name | Scott David Mcclellan |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 26 Years |
| Location | 2115 Neuse Blvd, New Bern, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609961853 | NPI | - | NPPES |
| P00375320 | Other | NC | RR MEDICARE |
| 14379 | Other | NC | BCBS PROVIDER NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ND0900X | Dermatology - Dermatopathology | 200000539 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carolina East Medical Center | New bern, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dermatology Associates Of Coastal Carolina Pa | 1658375092 | 12 |
News Archive
Tens of thousands of Massachusetts residents depend on home care to support their health as they age or cope with physical challenges. That care often requires close personal contact, increasing the risk of contracting COVID-19 among both home-care clients and the aides who provide their care.
Idera Pharmaceuticals, Inc. today announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis.
A study by a multidisciplinary research team, co-directed by Worcester Polytechnic Institute, offers new insights into how virulent fungi adapt through genetic modifications to fight back against the effects of medication designed to block their spread, and how that battle leaves them temporarily weakened. These insights may provide clues to new ways to treat notoriously difficult-to-cure fungal infections like thrush and vaginitis.
Two initiatives will improve access to health services for Albertans living in smaller communities by attracting more medical students to rural family medicine and putting more family physician residents into rural practice.
Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.
› Verified 3 days ago
| Entity Name | Dermatology Associates Of Coastal Carolina Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619903176 PECOS PAC ID: 1658375092 Enrollment ID: O20060828000107 |
News Archive
Tens of thousands of Massachusetts residents depend on home care to support their health as they age or cope with physical challenges. That care often requires close personal contact, increasing the risk of contracting COVID-19 among both home-care clients and the aides who provide their care.
Idera Pharmaceuticals, Inc. today announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis.
A study by a multidisciplinary research team, co-directed by Worcester Polytechnic Institute, offers new insights into how virulent fungi adapt through genetic modifications to fight back against the effects of medication designed to block their spread, and how that battle leaves them temporarily weakened. These insights may provide clues to new ways to treat notoriously difficult-to-cure fungal infections like thrush and vaginitis.
Two initiatives will improve access to health services for Albertans living in smaller communities by attracting more medical students to rural family medicine and putting more family physician residents into rural practice.
Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott David Mcclellan, MD Po Box 890283, Charlotte, NC 28289-0283 Ph: (252) 672-7745 | Scott David Mcclellan, MD 2115 Neuse Blvd, New Bern, NC 28560-4309 Ph: (252) 633-4461 |
News Archive
Tens of thousands of Massachusetts residents depend on home care to support their health as they age or cope with physical challenges. That care often requires close personal contact, increasing the risk of contracting COVID-19 among both home-care clients and the aides who provide their care.
Idera Pharmaceuticals, Inc. today announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis.
A study by a multidisciplinary research team, co-directed by Worcester Polytechnic Institute, offers new insights into how virulent fungi adapt through genetic modifications to fight back against the effects of medication designed to block their spread, and how that battle leaves them temporarily weakened. These insights may provide clues to new ways to treat notoriously difficult-to-cure fungal infections like thrush and vaginitis.
Two initiatives will improve access to health services for Albertans living in smaller communities by attracting more medical students to rural family medicine and putting more family physician residents into rural practice.
Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.
› Verified 3 days ago
Dr. James M Polo, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2115 Neuse Blvd, New Bern, NC 28560 Phone: 252-633-4461 Fax: 252-635-6951 | |
Dr. Sean James Murphy, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2115 Neuse Blvd, New Bern, NC 28560 Phone: 252-633-4461 Fax: 252-633-6016 | |
Kenneth L Klein, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 600 Mccarthy Blvd, New Bern, NC 28562 Phone: 252-633-4200 Fax: 252-633-9263 | |
Dr. Todd Brandon Nelson, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 941 Newman Rd, New Bern, NC 28562 Phone: 252-634-2885 | |
Dr. Christopher B Mizelle, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 941 Newman Rd, New Bern, NC 28562 Phone: 252-752-4124 Fax: 252-758-8954 |